A PHASE I/II DOSE FINDING AND EFFICACY STUDY OF THE TUMOUR TARGETING HUMAN 131I-L19SIP MONOCLONAL ANTIBODY IN PATIENTS WITH CANCER.
Phase of Trial: Phase I/II
Latest Information Update: 04 Dec 2013
At a glance
- Drugs Radretumab (Primary)
- Indications Cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Philogen
- 29 Apr 2011 Planned end date changed from 1 Feb 2011 to 1 May 2011 as reported by ClinicalTrials.gov.
- 16 Nov 2010 New trial record